## BLISS GVS PHARMA LTD.



January 11, 2018

To,
The Secretary,
The Bombay Stock Exchange,
PhirozeJeejeebhoy Towers
Dalal Street
Mumbai - 400001

## SUBJECT: BOARD MEETING OUTCOME

**BSE CODE: 506197** 

Dear Sir / Madam,

This is to inform you that the Board Meeting of the Company was held today i.e. January 11, 2018 at the registered office of the company at 03.00 p.m. to consider the potential disinvestment of one of our subsidiaries.

The Board has decided, after due deliberations, to divest the step down subsidiary of the company, Bliss GVS Healthcare Limited, Nairobi. This decision has been made essentially to lower dependence on Tender Driven Managed Healthcare business and focus on growing the Pharmaceuticals Business.

The draft proposal, related valuation report, fairness opinion report and other related documents thereto shall be placed before the Audit Committee on Friday, 19th January, 2018.

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to further inform you that the Board Meeting of the Company will be held on Friday, January 19, 2018 at the registered office of the Company at 12.00 p.m. to consider inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2017.

Kindly acknowledged and take on record the same.

Thanking You,

For BLISS GVS PHARMA LIMITED

VIPUL B. THAKKAR
CHIEF FINANCIAL OFFICER

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com